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Protein micro- and nano-capsules for biomedical
applications†
Ulyana Shimanovich,a Gonçalo J. L. Bernardes,*ab T. P. J. Knowlesa and
Artur Cavaco-Paulo*c
Micro- and nano-scale systems have emerged as important tools for developing clinically useful drug
delivery systems. In this tutorial review, we discuss the exploitation of biomacromolecules for this
purpose, focusing on proteins, polypeptides, nucleic acids and polysaccharides and mixtures thereof as
potential building blocks for novel drug delivery systems. We focus on the mechanisms of formation of
micro- and nano-scale protein-based capsules and shells, as well as on the functionalization of such
structures for use in targeted delivery of bioactive materials. We summarise existing methods for
protein-based capsule synthesis and functionalization and highlight future challenges and opportunities
for delivery strategies based on biomacromolecules.
Key learning points
(1) Many therapeutically active compounds cannot be delivered using conventional strategies due to undesired pharmacological properties and/or interactions
with cellular components during their delivery.
(2) To address this challenge, micro- and nano-scale systems have emerged as promising delivery systems enabling controlled transport and delivery, with
protein-based systems being particularly attractive components in this context.
(3) The fabrication of protein or hybrid protein/polymer micro- and nano-capsules requires control of compartmentalisation on the micro and/or nano-scale.
Several approaches are available to achieve this objective including emulsification and ultrasonic emulsification.
(4) A key challenge is to engineer the building blocks assembly pathways to encode the information required for the formation of capsules with desired
properties. Chemical synthesis and functionalization approaches can play a key role in this area.
(5) While many challenges remain to fully realise the utility of biopolymer based delivery vehicles, their versatility, biocompatibility and low immunogenicity
makes these materials a key addition to the palette of available delivery systems and open up new possibilities for biomedical applications. In addition, it is
possible to obtain protein-based particles with a reduced size (o100 nm), as required for many applications, while keeping proteins fully functional and
accessible as well as avert protein co-aggregation.
1. Introduction
To address the challenges associated with the controlled delivery
of active components for biomedical applications, encapsulation
methodologies with a high performance and tenability are
required.1 A powerful motivation for this line of research is
given by the observation that many clinically relevant drugs
cannot be administered using conventional release methods
due to unfavourable solubility and toxicology characteristics
and inappropriate interactions with other chemical species
during delivery.2–4 A class of materials that has emerged as
being particularly promising in this context is that of bio-
compatible polymers, protein capsules and hybrid polymer–
protein capsules. These structures consist of a polymeric shell
with dimensions on the micro- or nanoscale encapsulating
active species in their interior. Multiple synthetic pathways are
available to generate these materials,5 and a crucial challenge
is the engineering of the precursor components and the
assembly pathway to generate capsules with the desired
properties.6 For instance, chemical modification of precursor
components can lead to several distinct capsule structures.
Furthermore, significant structural complexity can be accessed
by combining different materials in the core and shell parts of
the capsules, for example in the form of hollow protein capsule
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shells,7 oil-filled protein capsule shells,8 water-filled protein
capsule shells9 and protein coated nucleic acid particles.10
The chemical properties of the building blocks can be used
to tune the material properties and structure of the final
capsules.11 Protein-based capsules can offer significant
advantages over purely synthetic systems, and the use of human
proteins as the precursor materials often results in delivery
materials with minimal immunogenecity.12 Several types of
protein-based capsules, their derivatives, and other bio-
compatible protein complexes have gained prominence for
the specific delivery of drugs to sites of disease while sparing
healthy tissues. Protein modification and/or coupling with
other functional molecules as well formulations of different
types of proteins can be used and enhance the versatility of
this class of materials. For instance, the engineering of
functionalized protein capsules, with an external hydrophobic
layer, can allow the incorporation of specific functionalities
at the surface of the capsule to include specificity to a pre-
determined target, enhance transdermal transport properties,
encode a release switch mechanism or even enhance the
biological effect of the active species delivered through the
capsules, for example by displaying antigens that will result
in an increased immune response in the case of vaccines.13 The
present tutorial review focuses on the synthesis pathways
available for the generation of protein capsules with controlled
properties. We discuss the most prevalent approaches, their
advantages and limitations and highlight the key challenges
and future opportunities in this area.
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There are a rich variety of methods described in the litera-
ture for the preparation of protein capsules and shells. One of
the most widely adopted methods to obtain micro- to nano-
scale capsules is based on micro-emulsion technology.14 This
approach builds on the use of two immiscible fluids, commonly
an oil phase and an aqueous phase, the former typically
carrying the active substance (a hydrophobic substance for
encapsulation in the organic phase and a hydrophilic sub-
stance for accumulation in the protein shell) to be encapsulated
and the latter one carrying the protein precursor molecules
used to form the shell. A micro-emulsion formed from these
two immiscible phases acts as a template for the synthesis of
the capsules around the interface of the phases. This approach
allows phase separation and a range of related physical or
chemical phenomena to be exploited, including variations in
surface tension, repulsive and attractive forces or specific
chemical interactions.15 The properties of the capsules are
closely controlled by the sizes and characteristics of the tem-
plate emulsions, and a wide range of approaches for the
controlled generation of micro-emulsions have been exploited.
These include bulk single emulsions,16 bulk double emul-
sions,17 polymerization techniques,18 phase separation coacer-
vation technique,19 spray drying and spray congealing,20
solvent extraction,21 microfabrication, and homogenization
and ultrasonic emulsification.22 These methods result in pro-
tein capsules with fundamentally diﬀerent properties, includ-
ing size and stability. When devising new synthetic strategies or
evaluating existing ones it is key to carefully evaluate the impact
of core functionalization on the thermodynamic and kinetic
stability of the resulting protein capsules. A significant influ-
ence on the stability of the final structures originates from the
properties of the materials that are used as precursor compo-
nents in the synthesis. For emulsification techniques that
rely on cavitation, notably sonication-based approaches, sono-
chemical processes can contribute to the cross-linking of the
capsule proteins without the need for specific chemical cross-
linking agents. In the following section we discuss existing
emulsification methods that are used for protein capsule
formation.
2. Current methods for protein micro/
nanocapsules production
In order to act eﬀectively as delivery agents, protein micro- and
nano-capsules should satisfy key criteria in respect of:
(a) Stability of the preparation after synthesis with a life
compatible with clinical practice.
(b) Controllable particle size and monodispersity in bio-
logical media used for injection.
(c) Biocompatibility and controllable biodegradability as
well as controllable release rate of the active reagent.
(d) Targeted delivery to specific sites of disease requires
amenability to chemical surface functionalization.
A range of approaches have been developed to fulfil these
criteria and are depicted in Fig. 1.
Single and double emulsion techniques16
To synthesise micro- or nano-containers from biopolymers by
using single emulsions (Fig. 1a), the precursor molecules,
commonly proteins, are dissolved or dispersed in the aqueous
medium followed by emulsification in a non-aqueous medium
such as oil. Next, to ensure structural integrity, chemical or
physical cross-linking of the dispersed droplet is carried out
(Fig. 1b). The cross linking can be achieved either intrinsically
by means of heat, or by using the chemical cross-linkers,
including glutaraldehyde, formaldehyde or diacid chloride
etc. Intrinsic cross-linking23 has the advantage of minimizing
potential toxicity and undesired reactivity with other chemical
components resulting from the presence of chemical cross
linkers.
More complex structures can be obtained through the use of
double emulsions (Fig. 1c).17 Similarly to the case of single
emulsions, the aqueous protein solution is dispersed in a
lipophilic organic continuous phase. The primary single
water-in-oil emulsion24 obtained in this manner is then added
to an aqueous solution of a second biopolymer that will then
form the outer shell of the capsule. This process hence results
in the formation of a double emulsion. The biggest advantage
of the capsules created by the double emulsion method over
capsules created via the single emulsion method is the possi-
bility of controlling independently the inner and outer surface
of the capsule. Capsules created via such a double emulsion
method allow encapsulation of water-soluble species and are
therefore well suited for the delivery of water-soluble drugs,
peptides, proteins and design of vaccines.
Phase separation coacervation technique19
Creation of protein capsules of specific sizes can also be
achieved by phase separation in solution rather than emulsifi-
cation. Colloidal systems, including polymer solutions, have
the propensity to undergo coacervation where a homogeneous
solution phase separates into two liquid phases, one of which is
essentially pure solvent, and the other contains the solute. In
the context of the creation of protein-based capsules, this
phenomenon is exploited based on the principle of decreasing
the solubility of the biopolymer (protein) to induce the forma-
tion of a protein rich phase, called the coacervates (Fig. 1d). In
this method, the drug particles to be delivered are initially
dispersed in a solution of the protein and then an incompatible
polymer is added to the system leading to the phase separation
of the protein and subsequent accumulation of the drug into
the protein rich phase. In order to enhance the stability of the
capsules formed through coacervation, in some cases, for
unstable proteins, a cross-linking agent is used prior to adding
the incompatible polymer.
Spray drying and spray congealing20,21
These methods are based on microdroplet spray generation
from a solution of the protein and the drug (Fig. 1e). The spray
can then undergo solvent removal in spray drying or rapid cooling
followed by freeze-drying in the case of spray congealing. One of
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the major advantages of the process is the feasibility of operat-
ing under aseptic conditions due to the absence of a liquid
phase, which could mediate contamination. This process has
been used for protein loaded lipid capsules.25,26
Ultrasonic emulsification technique27
The creation of protein capsules via the ultrasonic emulsifica-
tion method involves mechanical mixing, by the action of high-
intensity ultrasonic waves to a macroscopic oil/water interface.
As a result, an oil-in-water emulsion is created in which the
protein molecules, initially present in the aqueous phase,
localise at the interface of the droplet. The preparation of
capsules using ultrasound emulsification from aqueous protein
solutions and immiscible hydrophobic solvents is a well-known
technique and it has been the subject of recent reviews.22,28,29
Those reviews provide comprehensive information about the
mechanism of formation of protein capsules.27
The interfaces obtained through the emulsification methods
described above can be used to direct polymerization of soluble
precursor monomer molecules to form polymeric structures
on the surface of the emulsion. This approach (Fig. 1b) is
commonly applied to the generation of capsules from syn-
thetic polymers, but also holds great potential in the area of
protein-based capsules. Polymerization emulsification can be
combined with the emulsification approaches described above,
including, suspension, precipitation, emulsion and micellar
polymerization processes. An alternative approach to stabilize
protein-based capsules is to use them as templates to direct
the polymerization of the synthetic polymers on their sur-
face, leading to a coating that enhances the robustness of the
capsules.
Fig. 1 Schematic representation of emulsification methods used for protein capsule preparation: (a) single emulsification method; (b) polymerization
(cross-linking) method; (c) double emulsification method; (d) phase separation/coacervation method; (e) spray drying/spray congealing method; and
(f) ultrasonic emulsification method.
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Microfabrication method30
Monodispersed emulsions can be formed using the micro-
fabrication method, which enables precise control of the particle
size at micro/nano scale dimensions. The technique enables
manipulation of ultralow interfacial tensions at the surface of
emulsion droplets that results in a highly monodisperse emul-
sion. One of the most attractive features of the microfabrication
method is precise manipulation of emulsion composition.
3. Properties of protein capsules
3.1 Size
The size of the capsules is a key parameter that aﬀects the
ability of such particles to interface with biological systems and
influences the rate at which species can be released from
protein capsules. In methods involving emulsification, the
properties of the oil–water interface, including surface tension
and viscosity, can be used to tune the size of the droplets which
are used to template the capsules.31,32 In cases where the
hydrophobic phase remains encapsulated in the final structure,
its level of hydrophobicity can also influence the stability of the
capsule. For instance it has been found that food oils yield
more stable particles than dodecane, which is more hydro-
phobic (Fig. 2).27,28 Furthermore, intrinsic differences between
high viscosity food oils such as olive oil and low viscosity oils
such as soya bean oil can be used to tune the size of the resulting
capsules: capsules generated from a food oil with higher visco-
sity values leads to an increase in the size of the protein capsules,
but commonly also reduces their stability and fraction of protein
incorporated in such capsules.
A further parameter of interest is the ratio of hydrophobic
solvent to water in the precursor mixture. Low fractions of the
hydrophobic phase to the aqueous phase yield smaller cap-
sules, which are less stable relative to bigger capsules formed
with a higher organic solvent fraction (Fig. 2).27
Moreover, when the capsules are used to carry a drug like
small molecule, the chemical and physical nature of the
encapsulated drug can aﬀect not only the capsules’ sizes, but
also the hydrophobicity of the internal part of the capsule. For
example, the size dependence of BSA protein (Bovine Serum
Albumin) capsules has been shown to be aﬀected by the length
of encapsulated RNA molecules.31 These changes in size are
shown in Fig. 3a. The results demonstrate that the size of the
RNA loaded capsules increases with an increase of the number
of nucleotides in the RNA chain, i.e. with an increase in the size
of the encapsulated molecule. In parallel, the hydrophilicity of
the inner part of the protein capsule increases upon encapsula-
tion of a hydrophilic molecule such as RNA. For studies of
changes in the environment within capsules, environmentally
sensitive dyes such as Nile Red have proven to be very valuable
due to their ability to change their fluorescence spectrum upon
the change in solvent polarity. The red signal, indicating an
hydrophilic environment, emits from the shell of unloaded
capsules (Fig. 3b, top image). As soon as the protein spheres
were loaded with a hydrophilic RNA molecule, the inner
environment became more hydrophilic, and a red-shifted
Fig. 2 Schematic representation of size and stability studies for protein
aqueous microspheres as a function of peptide sequence, size of amphi-
philic peptides, aqueous/organic solvent ratio and type of organic solvent.
The scheme and microscopic image of a protein aqueous microsphere is
shown in the left corner. Scheme: the protein is localised at the water/oil
interface with hydrophobic residues (green) towards the oil phase and
hydrophilic (red) towards the water. Microscopy image: Nile Red coloured
protein microsphere filled with oil (green) in its inner part and protein (red)
forming the shell of the sphere. Schematic representation based on data
from reference.27
Fig. 3 Length of encapsulated RNA influences the size of protein cap-
sules. (a) Graphic represents size dependence of the protein capsules as a
function of the length of encapsulated RNA chain. (b) Fluorescent micro-
scopy images of Nile Red colored BSA spheres. Unloaded spheres are
presented on the top and RNA loaded on the bottom side.31 (c) 3D
confocal image of a fitc-BSA sphere loaded with Cy3RNA molecules.
Scale bars = 1 micrometer.
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emission signal of Nile Red dye, indicating a hydrophilic
environment, was observed from the shell as well as from the
inner part of the capsules (Fig. 3b, bottom image).
Furthermore, capsules can be formed from a mixture of two
diﬀerent proteins.32 Unlike in the case of capsule formation
from amixture of nucleic acids and proteins, where RNA loaded
BSA spheres were created, the mixture of two diﬀerent proteins
forms uniform protein capsules where two proteins co-localize
in the shell of the capsule.
An additional approach that enables control of the size of
protein-based particles has been recently reported.33 Incorpora-
tion of PEGylated surfactants (polyethyleneglycol-based surfac-
tants) into BSA based protein particles leads to decrease in
particle size from 200 to 100 nm. Particle formation in the
presence of PEGylated surfactants is physically restricted by
the steric eﬀect of the polymer (PEG) resulting in decrease in
the average protein particle size.
3.2 Stability
In general, an emulsion of oil and water, once formed, can be
unstable with respect to separation into two bulk phases, a
reflection of the fact that oil and water notoriously do not mix.
The stability of such emulsions is dependent on the protein
sequence and size, and may be enhanced by the presence of
surfactant molecules that are added to the precursor mixture.
Proteins are amphoteric enough to localize at the oil–water
interface and stabilize the emulsion, leading to an increase in
the lifetime of uncross-linked oil-filled protein spheres and
preventing the droplets from merging and reforming two bulk
phases. Disulfide bonding has been thought to be the most
prevalent contributor to protein capsule stability by formation
of cross-linking between proteins. However, a recent report shows
that the replacement of cysteine residues involved in disulfide
bonding by hydrophobic residues can result in stable capsules
(Fig. 2).27 Thus, stabilization of protein capsules may also be
achieved through a hydrogen network formed at hydrophobic
residues instead and/or in addition to covalent cross-linking. In
addition, the length of amphiphilic peptides determines the final
size and stability of the resulting protein capsules. A longer
amphiphilic peptide yields a larger and more stable protein
aqueous sphere (Fig. 2).27 Furthermore, it has been found that
the inner hydrophobic parts when exposed to the oil interface
may lead to a change of protein conformation, which results in
enhanced capsule stability (Fig. 2).27
The stability of mixed protein capsules can also be enhanced
through the addition of a biocompatible synthetic polymer to the
mixture of proteins. For example, the silk fibroin capsules, pre-
pared by the phase separation method, were shown to be stabi-
lised by polyvinylalcohol polymer (PVA).34 This stabilization can in
part originate from the change in the secondary structure
observed for silk fibroin following the addition of PVA. A further
agent that has been shown to stabilize protein capsules is poly-
ethylene glycol (PEG).35 In addition to the enhanced stability, the
interactions of the capsules with biological systems are modified
by pegylation. In particular, such capsules are often less immuno-
genic, resulting in the blocking and delaying of the first step in the
phagocytic process, oponisation. Thus, the pegylated capsule
shells have an increased half-life in blood circulation; this eﬀect
has been observed to reach up to several orders of magnitude. A
representative list of protein stabilizers is given in Table 1.
In view of their applications as delivery systems, an impor-
tant parameter of interest of protein capsules is their ability to
Table 1 List of main protein stabilizers
Type of protein stabilizers Protein stabilizers Function Protein storage
Cryoprotectants DMSO Prevent formation of ice crystals 20 1C
Ethylene glycol
Glycerol
2-Methyl-2,4-pentadiol (MPD)
Propylene glycol
Sucrose
Protease inhibitors PMSF (Phenylmethylsulfonyl fluoride):
inhibition of serine proteases
Inhibit protein activity and present
proteolytic cleavage of proteins
20 1C, 4 1C
Benzamidine: inhibition of serine proteases
Pepstatin A: inhibition of acid proteases
Leupeptin: inhibition of cysteine proteases
Aprotinin: inhibition of serine proteases
Antipain: inhibition of cysteine proteases
EDTA and EGTA: inhibition of metalloproteases
Antimicrobial agent Sodium azide Inhibit microbial growth in protein
solutions
4 1C
Ethylenediaminetetraacetic acid (EDTA)
Metal chelators Orthophenanthroline Inhibit metal-induced oxidation of free
thiols helping in maintaining the
protein in a reduced state
4 1C
Reducing agents Dithiothreitol (DTT) Maintain the protein in a reduced state 20 1C, 4 1C
2-Mercaptoethanol
Tris-(2-carboxyethyl)-phosphine hydrochloride (TCEP)
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interact with biological systems and in particular their bio-
compatibility. A key objective, therefore, is to develop chemi-
stry, which is compatible both with the structural requirements
as well as minimizing the toxicity of the capsules. The use of
potentially toxic covalent cross-linkers, for example, will lead to
capsule stabilization but, at the same time, can induce an
increase in toxicity of the resulting capsule. In order to circum-
vent this limitation, for emulsification methods such as tem-
plate based polymerization, suspension polymerization, etc.,
that commonly require the use of toxic chemical cross-linkers,
the toxicity can be alleviated by removal of the unreacted cross-
linkers post synthesis, leading in many cases to a reduction in
toxicity of the protein capsules. This additional step is not
required for synthesis methods that do not involve chemical
cross-linkers, including double emulsification, solvent extrac-
tion, and ultrasonic emulsification. In such cases, capsules can
be stabilized by native cross-linking in the form of covalent
bonds in inter-molecular disulfide bonds36 between two cysteine
residues in adjacent protein molecules or hydrophobic forces, or
hydrogen bonding networks,37 that are strong enough to hold
entire 3D protein capsules intact. The methods that lead to
creation of such a native supportive system for the protein
capsules are therefore of great interest due to the inherent non-
toxicity and biocompatibility. In order to favor the creation of
such native cross-linking networks some form of activation is
commonly required. In the case of ultrasonic emulsification,
the activation originates from the presence of superoxide
radicals formed upon the collapse of cavitation bubbles, favoring
S–S bond creation; a further effect of sonication is enhanced
mass-transfer from the flows generated by exposure to ultra-
sound. The activation as well as capsule formation occurs in a
one-step sonochemical reaction.
A summary of the diﬀerent emulsification methods that
have been used for the synthesis of diﬀerent types of protein
capsules and their basic properties are presented in Table 2.
Many of the capsules synthesized by emulsification methods
are found to be compatible with a role as delivery vehicles and
in many cases are either less toxic or non-toxic. Remarkable
diﬀerences from one emulsification method to another are
found in the capsules’ stability and average size (Table 2).
The use of ‘‘free of cross-linkers’’ methods (methods that do
not involve the use of chemical cross-linkers) is relatively new
in the field of interfaces. Thus, it is of great importance to
unveil the mechanism of protein capsules formation that does
not use cross-linkers, in particular for those capsules formed
using sonochemical procedures. The detailed mechanism of
formation of protein capsules is discussed below.
4. Mechanism and structural changes
accompanying the formation of
protein capsules
In order to optimize rationally the properties of protein cap-
sules, the mechanism leading to their formation is required.
A significant eﬀort has recently been focused in particular on
the formation of cross linker free capsules, especially in the
case of capsules that were formed sonochemically.22,27–29
Insights into the structural changes in the protein following
capsule formation have been gained by Fourier Transform Infra-
Red spectroscopy (FTIR) and molecular dynamic simulations.27
These studies showed that protein molecules accumulate
at the oil/water interface and undergo conformational changes
in their secondary and tertiary structures. In particular, an increase
of b-sheet content was found in silk fibroin microspheres while
molecular simulation has shown a twist of globular 3D struc-
ture (see protein conformation images on the top of the chart –
Fig. 4). The proteins are able to adjust their globular structures
upon binding to the interface by orienting the hydrophobic
residues towards the organic phase and the hydrophilic resi-
dues towards water; this transition results in a new energeti-
cally favorable 3D structure. The increase in b-sheet content of
the protein due to the ultrasonic spheridization is reminiscent
of amyloid-like behaviour, when protein molecules aggregate to
form densely hydrogen-bonded fibrillar structures.38,39
The protein conformations observed within the b-sheet rich
nanospheres might therefore have structural analogies with
bona fide amyloid fibrils. The possibility to form protein
capsules from proteins like silk fibroin and cysteine-free pep-
tides indicates the presence of further driving forces in addition
to covalent cross-linking, namely hydrophobic, electrostatic
interactions and enhanced mass transport, induced by ultra-
sound in liquid media.
Interestingly, this approach is not restricted to proteins.
Indeed, this strategy has been successfully used for the formation
of nanospheres made of nucleic acids,40–42 DNA and RNA, where
the stabilization of the spheres was proposed to be due to
hydrogen bonding, hydrophobic and electrostatic interactions
stabilized by counter ions (commonly Ca2+, Na+ and Mg2+).
The role of radicals in covalent cross-linking during ultra-
sonic capsule formation was studied by preventing the creation
of radicals in the reaction cell through performing the synthesis
under an inert (Ar) atmosphere. In all three cases where these
phenomena were probed for proteins as well as for nucleic acid
capsules, it was observed that capsules were successfully
formed even under an inert atmosphere and without the
presence of disulfide residues.40–42 These results demonstrated
that capsule stabilization can occur even in the absence of
covalent cross-linking. The formation of a hydrogen bonding
network connecting proteins in the capsule can be promoted by
organic solvents.43 In this work, the formation of a core–shell
structure made of Zein protein induced by the presence of citral
(3,7-dimethyl-2,6-octadienal) in the precursor mixture was
reported. The solvent ratio of binary solvents (ethanol 60–90%
and citral) affects the formation of core–shell structures. It was
shown that solvent polarity affected the ability of core material
(zein protein) to form small diameter droplets inside the shell.
The solvent with relatively high polarity (60% aqueous ethanol)
increased interfacial tension, leading to solidification of entire
zein spheres structure with no core. By contrast, low polarity
of the solvent (90% aqueous ethanol) decreased interfacial
tension, and allowed separation of the core material from
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shell material, thus leading to zein core–shell structure
formation.
The phenomenon of formation of hydrogen bonding net-
works makes the incorporation of two diﬀerent proteins in a
single capsule shell structure possible. The evidence for the
presence of a dense network of hydrogen bonds was reported
for the BSA-silk fibroin capsules.44 The protein capsule shell
made of a mixture of BSA and silk fibroin proteins showed the
characteristic FTIR absorption bands of the two proteins with
spectra of varying intensities due to the composition and
interactions of diﬀerent groups of proteins, confirming the
blending of the two proteins.
Another evidence of hydrophobic interactions in protein cap-
sule shell structure was reported by Subirade and co-workers.45
The whey protein granular capsule shells were stabilized by
adding calcium (Ca) alginate to the precursor protein solution.
The strong hydrophobic interactions created between hydro-
phobic side-chains of whey protein buried in the core of the
whey sphere and hydrophilic side chains facing alginate
resulted in enhanced stabilization of protein capsule structure.
5. Incorporation of functionalities at
the surface of the protein capsules
Tailoring of the surface chemistry of protein capsules allows for
control over the pathway and targeting of the protein capsules
inside the living systems as well as modification of the immu-
nogenicity of the particles.46 However, incorporating specific
surface modifications into the protein emulsions is challenging
Table 2 Summary of existing emulsification methods for protein capsules synthesis and protein capsules’ properties
Protein class Protein type Emulsification method Stability Capsules’ size Toxicity
Compatibility as
a ‘‘drug carrier’’
Globular Bovine Serum Albumin (BSA) Template based polymerization High 200 nm–5 mm Low Compatible
Coacervation High 150–200 mm Non-toxic Compatible
Single/Double emulsification High 200 nm–1 mm Non-toxic Compatible
Ultrasonic emulsification High 100 nm–3 mm Non-toxic Compatible
Globular Casein Coacervation High 150–200 mm Non-toxic Compatible
Single emulsification Average 2–50 mm Non-toxic Compatible
Suspension polymerization Low 200 nm–1 mm Low Compatible
Ultrasonic emulsification High 2–3 mm Non-toxic Compatible
Fibrous Collagen Phase separation Average 1–2 mm Average Compatible
Coacervation High 100–200 mm Non-toxic Compatible
Solvent extraction Average 100 nm–1 mm Non-toxic Compatible
Template based polymerization High 100 nm–1 mm Non-toxic Unknown
Globular alpha-protein Hemoglobin (Hb) Template based polymerization High 1–5 mm Low Compatible
Ultrasonic emulsification Average 1–2 mm Low Unknown
Globular plasma-protein Human Serum Albumin
(HSA)
Template based polymerization High 200 nm–5 mm Low Compatible
Single emulsification Average 10–60 mm Low Compatible
Coacervation High 500 nm–20 mm Low Compatible
Ultrasonic emulsification High 1–3 mm Low Compatible
Fibrous Insulin (INS) Template based polymerization High 200 nm–5 mm Low Compatible
Coacervation Low 600 nm–1 mm Average Unknown
Suspension polymerization High 20–100 mm Low Compatible
Fibrous Lysozyme (HEWL) Template based polymerization High 200 nm–5 mm Low Compatible
Fibrous Nonfimbrial adhesion (NFA) Suspension polymerization Unknown 50–250 nm Unknown Unknown
Fibrous Silk fibril (SF) Coacervation Low 200 nm–1.5 mm Low Unknown
Suspension polymerization High 100 nm–5 mm Non-toxic Compatible
Phase separation High 500 nm–1.5 mm Unknown Unknown
Ultrasonic emulsification High 500 nm–1.5 mm Low Compatible
Globular Soy protein isolate (SPI) Coacervation High 1–60 mm Non-toxic Compatible
Phase separation High 10–30 mm Non-toxic Compatible
Template based polymerization High 150 nm–2 mm Non-toxic Compatible
Single emulsification Average 10–60 mm Non-toxic Compatible
Ultrasonic emulsification High 1–2 mm Non-toxic Compatible
Globular Whey protein (WP) Electrospraying High 100 nm–1 mm Low Compatible
Globular Zein protein (ZP) Phase separation High 10–30 mm Non-toxic Compatible
Single emulsification Average 10–60 mm Non-toxic Compatible
Template based polymerization High 150 nm–2 mm Non-toxic Compatible
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and can compromise the structural characteristics of the cap-
sule and the process itself can require chemical conditions that
might lead to loss of biocompatibility and gain of toxicity of the
protein capsules for cells and organisms.
A number of methods have been described for the incor-
poration of functionalities on the surface of protein emulsions:
(1) construction of the protein capsules from a mixture of two
proteins that have two diﬀerent functionalities;32 (2) coating of
protein capsules with biocompatible polymers;47 (3) chemical
conjugation of polysaccharides to proteins,48 and (4) conjuga-
tion of target ligands, including folate, to the surface of protein
spheres.49 The list of bioactive ligands that are attractive
candidates for functionalization strategies has been reviewed
elsewhere.50 Below we review some representative examples of
functionalization of protein capsules.
A convenient approach for introducing new functionality
into a capsule is through the use of an additional protein with
the required properties. This can either be achieved through
co-assembly of distinct proteins from solution, or capsule for-
mation from a tandem construct of fused proteins. In this
manner, the same capsule shell can have a number of func-
tionalities. A specific example of this type of surface function-
alization by conjugation of a second protein to the main protein
capsule shell was described by Rahimipour and co-workers.51
In this case the protein BSA was chosen as the main structural
protein for capsule shell construction, whereas the KLVFF
peptide was used for capsule’s surface functionalization. The
KLVFF peptide is a known inhibitor of the amylogenic Ab-40
protein aggregation phenomenon that leads to Alzheimer’s
disease. The BSA protein-based capsule activated with the
KLVFF peptide induced the formation of amorphous Ab-40
aggregates with no fibrillar structure upon the incubation with
Ab on their surface.51
Protein capsules suitable for targeted delivery may also be
synthesized via alteration of surface charge of the protein
capsule by coating it with uncharged (e.g., PVA-polyvinylalcohol)
or positively charged (e.g., PEI-polyethileneimine) biocompatible
synthetic polymers. Moreover, coating of protein spheres with
magnetic (Fe2O3) nanoparticles enables specific delivery when
applying an external magnetic field. Both of these types of surface
coatings have been used to functionalize the surface of RNA loaded
proteinaceous BSA microspheres.47 When coated with PVA or PEI,
the native negative charge of the BSA is buried by the polymer
layer, eliminating the adhesion of uncoated capsules to the cell
membrane and allowing eﬃcient delivery of RNA into human
osteosarcoma U2OS cancer cells and Trypanosoma parasites.47 In
this context, the metal coating (Fe2O3) could be used to enhance
contrast in electron microscopy and allowed the spatial localiza-
tion of the capsules to be determined inside the parasites and
mammalian cancer cells.
An additional way of incorporating functionality into the
protein shells is the biochemical conjugation of a polysaccharide
and a protein prior to capsule formation through emulsification.
An example of this strategy was recently provided by Wong and
co-workers48 who demonstrated the incorporation of a fluores-
cently labelled saccharide into the precursor protein followed by
capsule formation of the construct.
The direct chemical conjugation of folic acid to the surface
of the BSA and human serum albumin (HAS) protein nano-
capsules has also been described.49 In this case, the folic acid
was pre-activated with a heterobifunctional cross-linker and
then coupled with primary amines on HSA nanocapsules. Folic
acid receptors are over-expressed in many diseases and these
folate-coated HSA nanocapsules have great potential to be used
for drug delivery in a number of disease settings.
6. Future directions and concluding
remarks
The field of protein capsules has seen remarkable development
in the last decade. Indeed, it is now possible to assemble
protein capsules of defined sizes and with pre-defined func-
tionalities. Such methods have enabled the design and assem-
bly of protein capsules for tissue specific drug-delivery. We
anticipate that these methods, together with recent advances in
methods for the site-specific modification of proteins,46 will
expand significantly the use of functionalised protein micro-
and nano-capsules for targeted drug-delivery, imaging or vacci-
nation. In the latter case, the requirement of presenting the low
immunogenic oligosaccharide in a protein carrier for an optimal
immune response52 makes oligosaccharide modified immuno-
genic protein nanospheres particularly attractive vaccine candi-
dates. The availability of a protein carrier for surface modifications,
the enhanced permeation and retention eﬀect in combina-
tion with active targeting by the protein capsule shell carriers
would enhance the therapeutic eﬀect of delivered agents
without increase in their toxicity. Thus, protein capsules have
the potential to become one of the safest and most eﬀective
therapeutic vectors.
Fig. 4 Chart summarizing BSA and silk fibroin secondary structure
changes due to protein shell formation based on FTIR measurements.
The secondary structure before (left hand side) and after (right hand side)
conversion of protein into protein capsule shells is presented at the top of
the chart, respectively to BSA and SF proteins. Schematic representation
based on data from reference.27
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